Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|October 4, 2021
Daily Medication Pearl: Glatiramer Acetate Injection (Copaxone) for Multiple Sclerosis
Author(s)Saro Arakelians, PharmD
Glatiramer acetate modifies immune processes that are believed to be responsible for the pathogenesis of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Glatiramer acetate injection (Copaxone)
Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Explanations:
- Dosage: For subcutaneous injection only; doses are not interchangeable
- Glatiramer acetate 20 mg/ml per day
- Glatiramer acetate 40 mg/mL 3 times per week
- Dosage forms: Injection of 20 mg/mL in a single-dose, prefilled syringe with a white plunger. Injection of 40 mg/mL in a single-dose, prefilled syringe with a blue plunger.
- Adverse events: Injection site reactions, vasodilatation, rash, dyspnea, and chest pain.
- Mechanism of action: Glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.
- Manufacturer: Teva
Sources
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5